22.05.2022 Views

DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Extracellular space

Mannoprotein

Glucan

Chitin

Glucan synthase

complex

Cell wall

Periplasm

Plasma membrane

Cytoplasm

Echinocandin

anti-fungal

Figure 57–3. The fungal cell wall and membrane and the action of echinocandins. The strength of the fungal cell wall is maintained

by fibrillar polysaccharides, largely β-1,3-glucan and chitin, which bind covalently to each other and to proteins. A glucan synthase

complex in the plasma membrane catalyzes the synthesis of beta-1,3-glucan; the glucan is extruded into the periplasm and incorporated

into the cell wall. Echinocandins inhibit the activity of the glucan synthase complex, resulting in loss of the structural integrity

of the cell wall. A subunit of glucan synthase designated Fks1p is thought to be the target of the echinocandin. Mutations in Fks1p,

coded for by FSK1, cause resistance to echinocandins.

as Histoplasma capsulatum. Echinocandins have no activity against

Cryptococcus neoformans, Trichosporon spp., or agents of

mucormycosis. In vitro studies have consistently failed to show synergism

or antagonism between echinocandins and amphotericin B.

There is no antagonism between echinocandins and azoles; an additive

effect has been reported with Aspergillus in some in vitro systems

and animals models. Echinocandin resistance can be selected

in Candida albicans under drug pressure both in vitro and clinically

during prolonged echinocandin therapy. Resistance is from mutations

in a conserved region of the FKS1 gene, coding for amino acids

Phe 641 -Asp 658 (Park et al., 2005). FKS1p is an essential component

of the 1,3-β-D-glucan synthase complex (Figure 57–3).

Caspofungin

Caspofungin acetate (CANCIDAS) is a water-soluble,

semisynthetic lipopeptide synthesized from the fermentation

product of Glarea lozoyensis (Johnson and

Perfect, 2003; Keating and Figgit, 2003).

Table 57-7

Pharmacokinetics of Echinocandins in Humans

DRUG DOSE (mg) C max

(μg/mL) AUC 0-24h

(mg•h/L) t 1/2

(h) Cl (mL/min/kg) V d

(L)

Caspofungin 70 12 93.5 10 0.15 9.5

Micafungin 75 7.1 59.9 13 0.16 14

Anidulafungin 200 7.5 104.5 25.6 0.16 33.4

For details, see Wagner et al. (2006).

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!